Geodon (Ziprasidone)

Even though there are warnings associated with ziprasidone due to its potential to prolong the QT interval, it still has a place in therapy - Mandy Leonard PharmD

Geodon (Ziprasidone)
Geodon (Ziprasidone)

image by: E.B. Zidentopff

HWN Suggests

Ziprasidone Unzipped

The controversy surrounding ziprasidone as being an antipsychotic with a higher risk of QTc prolongation and possibly torsade de pointes needs to be understood in context. While ziprasidone does appear to cause a greater degree of QTc prolongation than the other atypical antipsychotics, the average interval lengthening of 20ms in one study was significantly less than that of thioridazine, and torsade de pointes and sudden death have not been conclusively associated with ziprasidone.

Ziprasidone is therefore now generally considered as safe as the other atypical antipsychotics with respect to cardiac arrhythmias. Nonetheless, ziprasidone should be used with particular caution…

read full article

Resources

 Ziprasidone Unzipped

Ziprasidone is an atypical antipsychotic characterised by a low incidence of metabolic adverse effects and similar efficacy to other non-clozapine atypical antipsychotics. While there has been some concern about its cardiac effects, these are unlikely to be clinically significant in most patients.

Geodon

GEODON is not approved for the treatment of patients with dementia-related psychosis. Elderly patients with dementia-related psychosis (having lost touch with reality due to confusion and memory loss) treated with this type of medicine are at an increased risk of death, compared to sugar pill.

NAMI

Ziprasidone is a medication that works in the brain to treat schizophrenia. It is also known as a second generation antipsychotic (SGA) or atypical antipsychotic. Ziprasidone rebalances dopamine and serotonin to improve thinking, mood, and behavior.

NeuRA

High quality evidence suggests ziprasidone improves mental state more than placebo, although moderate quality evidence suggests ziprasidone causes more drowsiness and use of anti-parkinsonian medication. High quality evidence suggests ziprasidone results in better study retention than haloperidol, and moderate quality evidence suggests ziprasidone may be less likely to cause a movement disorder, but may increase the incidence of gastrointestinal symptoms, than haloperidol.

StatPearls

Ziprasidone is an atypical antipsychotic that has a binding affinity for dopaminergic (DA), serotonergic (5HT), adrenergic (a1), and histaminergic (HA) receptors.

Introducing Stitches!

Your Path to Meaningful Connections in the World of Health and Medicine
Connect, Collaborate, and Engage!

Coming Soon - Stitches, the innovative chat app from the creators of HWN. Join meaningful conversations on health and medical topics. Share text, images, and videos seamlessly. Connect directly within HWN's topic pages and articles.


Be the first to know when Stitches starts accepting users


Stay Connected